Sanofi Q2 2025 Financial and Operational Highlights

SEC Filing 6-K (0001121404-25-000020)

Sanofi reported strong Q2 2025 results with a 10.1% increase in sales at constant exchange rates (CER), driven by key products like Dupixent, which saw a 21.1% growth in sales. The company achieved a business EPS of €1.59, up 8.3% at CER. Sanofi also made significant progress in its pipeline, with three regulatory approvals and seven regulatory designations. The company refined its 2025 sales guidance to the upper end of the previous range, anticipating high single-digit growth. Additionally, Sanofi completed the Opella transaction, creating an independent global consumer healthcare leader, and continued its €5 billion share buyback program, with 80.3% completed by the end of Q2.